Highly sensitive and specific urine-based tests to detect either primary or recurrent bladder cancer have proved elusive to date. Our ever increasing knowledge of the genomic aberrations in bladder cancer should enable the development of such tests based on urinary DNA
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Current non-invasive approaches for detection of urothelial cancers are suboptimal. We developed a t...
Background: Highly sensitive and specific urine-based tests to detect either primary or recurrent b...
<div><p>Background</p><p>Highly sensitive and specific urine-based tests to detect either primary or...
BACKGROUND There is an unmet need for an accurate, validated, noninvasive test for diagnosing and...
BACKGROUND: There is an unmet need for an accurate, validated, noninvasive test for diagnosing and m...
BACKGROUND: There is an unmet need for an accurate, validated, noninvasive test for diagnosing and m...
BACKGROUND: There is an unmet need for an accurate, validated, noninvasive test for diagnosing and m...
Objectives To develop a focused panel of somatic mutations (SMs) present in the majority of urotheli...
Background: Bladder cancer (BC) is one of the most common cancers in the western world and ranks as...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Current non-invasive approaches for detection of urothelial cancers are suboptimal. We developed a t...
Background: Highly sensitive and specific urine-based tests to detect either primary or recurrent b...
<div><p>Background</p><p>Highly sensitive and specific urine-based tests to detect either primary or...
BACKGROUND There is an unmet need for an accurate, validated, noninvasive test for diagnosing and...
BACKGROUND: There is an unmet need for an accurate, validated, noninvasive test for diagnosing and m...
BACKGROUND: There is an unmet need for an accurate, validated, noninvasive test for diagnosing and m...
BACKGROUND: There is an unmet need for an accurate, validated, noninvasive test for diagnosing and m...
Objectives To develop a focused panel of somatic mutations (SMs) present in the majority of urotheli...
Background: Bladder cancer (BC) is one of the most common cancers in the western world and ranks as...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1...
Current non-invasive approaches for detection of urothelial cancers are suboptimal. We developed a t...